UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 91

Sortiert nach

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia

Frontiers in pharmacology, 2019-04, Vol.10, p.454-454

Calvo, Roser

2019

Volltextzugriff (PDF)

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

Haematologica (Roma), 2024-01, Vol.109 (1), p.343

2024

Volltextzugriff (PDF)

Altered HOX and WNT7A Expression in Human Lung Cancer

Proceedings of the National Academy of Sciences - PNAS, 2000-11, Vol.97 (23), p.12776-12781

2000

Volltextzugriff (PDF)

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

Blood advances, 2024-09, Vol.8 (17), p.4539-4548

2024

Volltextzugriff (PDF)

A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma

British journal of haematology, 2022-10, Vol.199 (1), p.76-85

2022

Volltextzugriff (PDF)

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Blood, 2022-11, Vol.140 (Supplement 1), p.6477-6479

2022

Volltextzugriff (PDF)

Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)

Blood, 2021-11, Vol.138 (Supplement 1), p.2416-2416

2021

Volltextzugriff (PDF)

ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS7572-TPS7572

2021

Volltextzugriff (PDF)

Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial

Blood, 2022-11, Vol.140 (Supplement 1), p.3606-3608

2022

Volltextzugriff (PDF)

Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7549-7549

2022

Volltextzugriff (PDF)

Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma

Leukemia & lymphoma, 2022-06, Vol.63 (7), p.1728-1732

2022

Volltextzugriff (PDF)

DEF-3(G16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC

Oncogene, 1999-04, Vol.18 (16), p.2589-2597

1999

Volltextzugriff (PDF)

Phase I study of volasertib combined with azacitidine in patients with previously untreated, high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) ineligible for high-intensity therapy

Clinical lymphoma, myeloma and leukemia, 2015-06, Vol.15, p.S233-S233

2015

Volltextzugriff (PDF)

Are laboratory parameter

Drug design, development and therapy, 2018-01, Vol.10, p.2757

2018

Volltextzugriff (PDF)

Genetic Susceptibility Associated with Rare HRAS1 Variable Number of Tandem Repeats Alleles in Spanish Non-Small Cell Lung Cancer Patients

Clinical cancer research, 1999-07, Vol.5 (7), p.1849-1854

1999

Volltextzugriff (PDF)

Are laboratory parameter (biomarker) values similar to the healthy volunteer reference range in all patient populations?

Drug design, development and therapy, 2018-01, Vol.12, p.2757-2773

2018

Volltextzugriff (PDF)

Josep Vallverdú, un escriptor de dietaris?

Ítaca. Revista de Filologia, 2010-12 (1), p.65-75

Calvo Mayor, Roser

2010

Volltextzugriff (PDF)

Embryonic genes in cancer

Annals of oncology, 2000, Vol.11 (suppl-3), p.207-218

2000

Volltextzugriff (PDF)

Embryonic genes in cancer

Annals of oncology, 2000, Vol.11, p.207-218

2000

Volltextzugriff (PDF)

Reduced survival in patients with stage‐I non‐small‐cell lung cancer associated with DNA‐replication errors

International journal of cancer, 1997-06, Vol.74 (3), p.330-334

1997

Volltextzugriff (PDF)

H-RAS 1 Minisatellite Rare Alleles: A Genetic Susceptibility and Prognostic Factor for Non-Hodgkin's Lymphoma

JNCI : Journal of the National Cancer Institute, 1998-07, Vol.90 (14), p.1095-1098

1998

Volltextzugriff (PDF)

Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis

European radiology, 2021-03, Vol.31 (3), p.1460-1470

2021

Volltextzugriff (PDF)

Serum branch-chained amino acids are increased in type 2 diabetes and associated with atherosclerotic cardiovascular disease

Cardiovascular diabetology, 2023-09, Vol.22 (1), p.1-10, Article 249

2023

Volltextzugriff (PDF)

Lipidomics of triglyceride‐rich lipoproteins derived from hyperlipidemic patients on inflammation

European journal of clinical investigation, 2024-03, Vol.54 (3), p.e14132-n/a

2024

Volltextzugriff (PDF)

1 – 25 von 91

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(80)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia

Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

Altered HOX and WNT7A Expression in Human Lung Cancer

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)

ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL)

Acalabrutinib Plus Rituximab with or without Lenalidomide in Patients with Follicular Lymphoma: A Multipart, Open-Label, Phase 1b Trial

Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial

Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma

DEF-3(G16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC

Phase I study of volasertib combined with azacitidine in patients with previously untreated, high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) ineligible for high-intensity therapy

Are laboratory parameter

Genetic Susceptibility Associated with Rare HRAS1 Variable Number of Tandem Repeats Alleles in Spanish Non-Small Cell Lung Cancer Patients

Are laboratory parameter (biomarker) values similar to the healthy volunteer reference range in all patient populations?

Josep Vallverdú, un escriptor de dietaris?

Embryonic genes in cancer

Embryonic genes in cancer

Reduced survival in patients with stage‐I non‐small‐cell lung cancer associated with DNA‐replication errors

H-RAS 1 Minisatellite Rare Alleles: A Genetic Susceptibility and Prognostic Factor for Non-Hodgkin's Lymphoma

Minimizing acquisition-related radiomics variability by image resampling and batch effect correction to allow for large-scale data analysis

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

Serum branch-chained amino acids are increased in type 2 diabetes and associated with atherosclerotic cardiovascular disease

Lipidomics of triglyceride‐rich lipoproteins derived from hyperlipidemic patients on inflammation

Suchergebnisse filtern